Antimicrobial treatment for Systemic Candidiasis.

Slides:



Advertisements
Similar presentations
From Guidelines to Bedside: Clinical Case Scenario Approach Mazen Kherallah, MD, FCCP.
Advertisements

Dr. Kouros Aghazade Shahid Beheshti Medical University
Fungal Infections, Pathogenesis and Treatment
Candidiasis C. Charunee 9/4/50.
Flucoral® Pharmacological Composition Each capsule containing 150mg Fluconazole. Fluconazole is a broad spectrum Systemic Antifungal.
OPPORTUNISTIC FUNGAL INFECTIONS
Identify patient at risk for Candida infection Major risk factors includeOther risk factors include Previous bacterial infection and therapy Tunneled venous.
Fungi Plant-like organisms that lack chlorophyll 1 of the 5 Kingdoms
ANTIFUNGAL DRUGS.
Fungal Infection in the ICU
Fungal infections Lobna AL Juffali,Msc.
ANTIFUNGAL DRUGS Fungal infections (mycoses) can be both superficial and systemic. Superficial infections (Oral and vulvovaginal candidiasis, Dermatophytosis,
Initial Antifungal Therapy for Critical Ill Patients When and Which ? 林口長庚 胸腔內科 林鴻銓 Lin, Horng-Chyuan Division of Pulmonary Infectious & Immunological.
Clinical Scenario  A 42 year old white female was admitted to the hospital with hematemesis and melena. The patient had a history of cirrhosis with ascites.
Eunice Huang, MD, MS APSA Education Day Palm Desert, CA May 22, 2011
Candida Fungemia Risks and Therapy Hail M. Al-Abdely, M.D. Associate Consultant King Faisal Specialist Hospital.
Management of Neutropenic Fevers in cancer patients Jerry Yu.
Combination Antifungal Therapy By Amy Barnett, Doctor of Pharmacy Candidate University of Florida College of Pharmacy.
Fungal infections 400 out of 75,000 Primary infections Opportunistic infections Myco-toxins Allergy.
Antifungal Drugs.
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Mucocutaneous Candidiasis Slide Set Prepared.
PRESENTER: HALIMATUL NADIA M HASHIM SUPERVISOR: DR NIK AZMAN NIK ADIB.
Which drugs?. Mode of action of antifungals ergosterol polyenes e.g. amphotericin B polyenes azoles e.g. fluconazole azoles nucleosides e.g. 5-flucytosine.
Selection of an optimal antifungal for treatment of invasive aspergillosis: susceptibility/resistance, adverse reactions, drug interactions John Bennett,
Flucoral capsules Product knowledge. Pharmacokinetics of fluconazole Distribution of Fluconazole is extensive and even throughout tissues. The high polarity.
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Aspergillosis Slide Set Prepared by the AETC.
Systematic review + meta-analysis: 69 (quasi-)randomised trials: N=7,863 pts with sepsis: any BL monoTx vs any combination of BL + AG: N (studies) : same.
BIBLE PAPER 26 AUG 2015 CANDIDA GLABRATA ESOPHAGITIS: ARE WE SEEING THE EMERGENCE OF A NEW AZOLE-RESISTANT PATHOGEN? WILSON A, DELPORT J, PONICH T. INT.
Diversity of Fungi and Fungal Infections
PRINCIPLES OF ANTIMICROBIAL THERAPY
Opportunistic mycosis Dr.Huda Ibrahim
ANTIFUNGAL DRUGS PHARM 514 Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington
Candidaemia in Critically Ill Patients Dr Bunny Saberwal, Mrs Rakhee Patel, Dr Seng Zhi Quan and Dr A. Gonzalez ICE 2.
Managing Candidemia JEANNE FORRESTER, PHARMD, BCPS PGY2 INFECTIOUS DISEASES PHARMACY RESIDENT MEDICAL UNIVERSITY OF SOUTH CAROLINA.
Fungal endophthalmitis
Dr C Sriruttan Clinical Microbiology & Infectious Disease /11/20161 Principles & Approach.
Expanded Therapeutic Options in the Treatment of Invasive Candidiasis Mazen Kherallah, MD, FCCP Critical Care & Infectious Disease Consultant King Faisal.
1. Candida 의 항진균제 감수성과 항진균제 간의 교차내성 2. Disseminated candidiasis 의 치료 약제 선택 3. Refractory case 에서의 치료 약제 선택.
Candidiasis A primary or secondary mycotic infection caused by members of the genus Candida. The clinical manifestations may be acute, subacute or chronic.
La terapia antifungina nel paziente critico Francesco Menichetti, MD Head, Infectious Diseases Unit Ospedale Nuovo Santa Chiara Pisa, Italy SIMIT 2015.
Candidiasis Downloded from
Outline of the Presentation
Empirical versus Preemptive Antifungal Therapy for High-Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial Clinical Infectious Diseases.
Risk Factors for Candida dubliniensis Bloodstream Infections Katherine Veltman, B.S., Peggy L. Carver, Pharm.D, FCCP The University of Michigan Health.
Prepared by the AETC National Coordinating Resource Center based on recommendations from the CDC, National Institutes of Health, and HIV Medicine Association/Infectious.
MANAGEMENT OF NEUTROPENIC FEVERS IN CANCER PATIENTS Jerry Yu.
Introducing ‘Sepsis 6’ at RACH. Important definitions SIRS Sepsis Severe sepsis Septic shock.
Prepared by the AETC National Coordinating Resource Center based on recommendations from the CDC, National Institutes of Health, and HIV Medicine Association/Infectious.
Medicine II Homework January 6, 2010 Subsection B4 Facilitator: Remedios F. Coronel, M.D.
Fungal Peritonitis (FP) Constantinos J. Stefanidis “P. and A. Kyriakou” Children’s Hospital Athens, Greece.
Fungal Infections and Antifungals in ICU
Antifungal drugs Lec Dr. Naza M. Ali
University Health Network
Therapeutics 3: Antibiotics Tutoring
Antifungal prophylaxis in liver transplantation
Brielle Haas RISE Spring 2015 Dr. Gullo
Diversity of Fungi and Fungal Infections
Clinical Case Conference #5
Staten Island University Hospital, Staten Island, New York, USA
Mycology.
Fungal endophthalmitis
بسم االه الرحمن الرحیم کاندیدیازیس.
This slide set is meant to be used as an adjunct resource to the Medscape program titled “Managing Invasive Candidiasis: A Systematic Approach” by Thomas.
5/23/2013 hammoud.
Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non- neutropenic models of invasive candidiasis  N.P. Wiederhold, L.K.
Intra-Abdominal Candidiasis, Candida peritonitis
بنام خداوند جان و خرد بنام خداوند جان و خرد.
Management of systemic fungal infections
Lecturer name: Dr. Ahmed M. Albarrag
Presentation transcript:

Antimicrobial treatment for Systemic Candidiasis

Systemic Candidiasis 2 primary syndromes: 1. Candidemia 2. Disseminated candidiasis

Candidemia - associated with several days of fever unresponsive to antimicrobials, prolonged IV catheterization, multi organ infection -others: intravascular catheter-related candidiasis, suppurative thrombophlebitis, endocarditis

Disseminated candidiasis -frequently associated with multiple deep organ infections or may involve single organ infection. - Candida osteomyelitis, arthritis, endocarditis, pericarditis, and meningitis, requires prolonged antifungal therapy for at least 4-6 weeks. - The history of a patient with presumptive disseminated candidiasis reveals a fever unresponsive to broad-spectrum antimicrobials and negative results from blood culture. - Physical examination reveals fever (may be the only symptom) with an unknown source and associated sepsis and septic shock.

Antimicrobial agents DRUGINDICATIONREMARKS Azole - Fluconazole (IV/oral) - drug of choice in most cases of candidemia and disseminated candidiasis. (in non- neutropenic and hemodynamicaly stable patients - lower nephrotoxicity rates (<2%) and ease of use because of the high degree of bioavailability and the long half-life of the drug - Voriconazole (IV/Oral) - If additional mold coverage is desired - used in neutropenic and hemodynamicaly unstable patients Echinocandins (Capsofungin IV) -recommended for candidemia in most patients with neutropenia. -Caspofungin is a broad- spectrum - It is an effective alternative for severe mucosal infections and systemic infections due to Candida, especially those due to non-albicans Candida species

-recommended for candidemia in most patients with neutropenia.- Caspofungin is a broad-spectrum semisynthetic echinocandin. It is an effective alternative for severe mucosal infections and systemic infections due to Candida, especially those due to non- albicans Candida species such as C glabrata. - It is an effective alternative for severe mucosal infections and systemic infections due to Candida, especially those due to non-albicans Candida species such as C glabrata.- can be initiated as a 70-mg loading dose, followed by 50 mg/d intravenously to complete a minimum of 2 weeks of antifungals after improvement and after blood cultures have cleared. Anudilafungin IV - Anidulafungin is a broad- spectrum echinocandin. It is an effective alternative for severe mucosal infections and systemic infections due to candida - be initiated as a 200-mg loading dose, followed by 100 mg intravenously to complete a minimum of 2 weeks of antifungals after improvement and after blood cultures have cleared. Micafungin IV It has been shown to be an effective alternative for severe mucosal infections and systemic infections due to Candida, especially those due to non- albicans Candida species - administered at 100 mg/d intravenously to complete a minimum of 2 weeks of antifungals after improvement and after blood cultures have cleared.